Veracyte News & Media Coverage 

Explore external media coverage featuring Veracyte in news articles, interviews, and industry publications worldwide. 

Media Inquiries

Get in touch with our communications team

[email protected]

+1 858-742-1258

Simply Wall St March 2026

How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story

Read More
Genome Web March 2026

Veracyte: Kevin Haas

Read More
Seeking Alpha February 2026

Veracyte outlines 10%–13% revenue growth for 2026 while advancing MRD and Prosigna launches

Read More
Nasdaq February 2026

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

Read More
Genome Web February 2026

Following Strong 2025 Results, Veracyte Expects Continued Double-Digit Revenue Growth in 2026

Read More
GenomeWeb May 2025

New Data Promising for Veracyte on Path to Launch Whole-Genome Sequencing MRD Test

Read More
Investor's Business Daily December 2024

Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics

Read More
GenomeWeb December 2024

Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests

Read More
GenomeWeb November 2024

Veracyte Further Cements Data on Core Prostate Test as Q3 Revenues Climb 29 Percent

Read More
Oncology Times October 2024

Genetic Test Predicts Survival Benefit From Docetaxel in Prostate Cancer

Read More

​​​​​Investor news alerts

Receive email updates with financial reports, SEC filings, press releases, and upcoming events.

Sign Up

Keep exploring

Press Releases

New data, partner announcements, and financial reports.

Learn More

Veracyte Diagnostics Platform

A novel diagnostics platform helping unlock deeper cancer insights.

Discover

Blog

Inspiring stories and latest clinical advances.

Learn More

Technology and Pipeline

Explore our portfolio of molecular tests, developments, and progress.

Discover

Connect with us 

Contact Us